Mast Therapeutics And Savara Announce Approval To List Common Stock On The Nasdaq Capital Market
"As home to many innovative and growth-oriented life science companies, Nasdaq is a natural fit for Savara," said
Mast will hold a special meeting of its stockholders to vote on matters related to the proposed merger with Savara on
The merger has been unanimously approved by the boards of directors of both companies and Mast urges its stockholders to vote "FOR" the merger and the other proposals set forth in the proxy statement/prospectus/ information statement dated
THE MERGER WILL NOT GO FORWARD UNLESS
THE MERGER, REVERSE STOCK SPLIT AND NAME CHANGE PROPOSALS
ARE ALL APPROVED.
If you are a Mast stockholder and you have questions or require assistance in submitting your proxy or voting your shares, please contact Mast's proxy solicitor:
ADVANTAGE PROXY, INC.
Toll Free: 1-877-870-8565
Additional Information about the Proposed Merger and Where to Find It
In connection with the proposed merger,
This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities in connection with the proposed merger shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
Participants in the Solicitation
Mast and its directors and executive officers and Savara and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Mast and Savara in connection with the proposed transaction. Information regarding the special interests of these directors and executive officers in the proposed merger is included in the proxy statement/prospectus/information statement referred to above. Additional information regarding the directors and executive officers of Mast is also included in Mast's Annual Report on Form 10-K for the year ended
Forward Looking Statements
Mast and Savara caution you that statements in this press release that are not a description of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as "expect," "intend," "plan," "anticipate," "believe," and "will," among others. Such statements include, but are not limited to, statements regarding the structure, timing and completion of the proposed merger; expectations regarding listing and trading of Mast's common stock on the NYSE MKT and of the combined organization's common stock on the
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mast-therapeutics-and-savara-announce-approval-to-list-common-stock-on-the-nasdaq-capital-market-300436986.html
Mast Therapeutics, Ioana C. Hone (firstname.lastname@example.org), 858-552-0866 Ext. 303